Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, England and RICHMOND, Va., April 20, 2018 /CNW/ -- Indivior PLC (LON: INDV ...

SLOUGH, England and RICHMOND, Va., April 5, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE ...

Indivior announced the availability of Sublocade (buprenorphine extended-release) subcutaneous injection for the treatment of moderate to severe opioid use disorder (OUD) in adults who have ...

SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are ...

Sublocade offers important benefits not currently provided by the sublingual form of buprenorphine. Medication is steadily released into the blood stream, which helps patients to be compliant with ...

In a 24-week, Phase 3 study (RB-US-13-0001), patients were randomized to 6 once-monthly Sublocade 300mg doses, 2 once-monthly Sublocade 300mg doses + 4 once-monthly 100mg doses, or 6 once-monthly ...

Oral forms of buprenorphine have been available to treat addiction since 2002 and can be purchased as a generic for less than $100 a month. Injectable buprenorphine, sold under the brand name ...

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release ...

Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by Indivior, Inc. has been granted Priority ...

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire ...

Patients were randomized at a 2:1 ratio to rapid initiation [received a single dose of 4 mg transmucosal buprenorphine (TM-BUP), followed by a SUBLOCADE injection within one hour] or to a standard ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...